Sofosbuvir plus daclatasvir for 12 weeks cures most HIV/HCV coinfected patients
Linuxter said
Feb 16, 2016
Pretty incredible stats!
I would imagine a virtual gold mine for anyone co-infected ...
I'm glad to see progress being made here.
Thanks for the article Jill!
Dave
Cinnamon Girl said
Jun 4, 2015
Nearly all HIV/HCV coinfected patients treated for 12 weeks with an interferon- and ribavirin-free regimen of sofosbuvir (Sovaldi) and daclatasvir (Daklinza) achieved sustained virological response, but the cure rate fell to 76% for those treated for only 8 weeks, according to results from the ALLY-2 trial presented at Digestive Disease Week 2015 last month in Washington, DC.
Kenneth Sherman of the University of Cincinnati presented findings from the phase 3 ALLY-2 trial, which evaluated Gilead Sciences' nucleotide polymerase inhibitor sofosbuvir plus Bristol-Myers Squibb's NS5A inhibitor daclatasvir without ribavirin. Daclatasvir is pangenotypic - meaning it works against multiple HCV genotypes - unlike ledipasvir, the NS5A inhibitor in Gilead's Harvoni coformulation.
Sherman reported that 96% of genotype 1 treatment-naive patients and 98% of treatment-experienced patients treated for 12 weeks achieved sustained virological response, or undetectable HCV RNA 12 weeks after completing treatment (SVR12). The sustained response rate fell to just 76%, however, for genotype 1 treatment-naive patients treated for only 8 weeks.
Response rates were similar when looking at all genotypes combined. Everyone with genotype 2, 3 or 4 who was treated for 12 weeks achieved SVR12.
People with cirrhosis had somewhat lower cure rates than non-cirrhotic patients in both the 8-week arm (60% vs 77%) and in the 12-week arms (91% vs 99%).
Pretty incredible stats!
I would imagine a virtual gold mine for anyone co-infected ...
I'm glad to see progress being made here.
Thanks for the article Jill!
Dave
Nearly all HIV/HCV coinfected patients treated for 12 weeks with an interferon- and ribavirin-free regimen of sofosbuvir (Sovaldi) and daclatasvir (Daklinza) achieved sustained virological response, but the cure rate fell to 76% for those treated for only 8 weeks, according to results from the ALLY-2 trial presented at Digestive Disease Week 2015 last month in Washington, DC.
Kenneth Sherman of the University of Cincinnati presented findings from the phase 3 ALLY-2 trial, which evaluated Gilead Sciences' nucleotide polymerase inhibitor sofosbuvir plus Bristol-Myers Squibb's NS5A inhibitor daclatasvir without ribavirin. Daclatasvir is pangenotypic - meaning it works against multiple HCV genotypes - unlike ledipasvir, the NS5A inhibitor in Gilead's Harvoni coformulation.
Sherman reported that 96% of genotype 1 treatment-naive patients and 98% of treatment-experienced patients treated for 12 weeks achieved sustained virological response, or undetectable HCV RNA 12 weeks after completing treatment (SVR12). The sustained response rate fell to just 76%, however, for genotype 1 treatment-naive patients treated for only 8 weeks.
Response rates were similar when looking at all genotypes combined. Everyone with genotype 2, 3 or 4 who was treated for 12 weeks achieved SVR12.
People with cirrhosis had somewhat lower cure rates than non-cirrhotic patients in both the 8-week arm (60% vs 77%) and in the 12-week arms (91% vs 99%).
Full article...
http://www.aidsmap.com/Sofosbuvir-plus-daclatasvir-for-12-weeks-cures-most-HIVHCV-coinfected-patients/page/2973850/